Treatment outcomes for infantile spasms in Japanese children with Down syndrome.


Journal

Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002

Informations de publication

Date de publication:
Dec 2021
Historique:
revised: 22 01 2021
received: 11 07 2020
accepted: 24 02 2021
pubmed: 28 2 2021
medline: 15 12 2021
entrez: 27 2 2021
Statut: ppublish

Résumé

The aim of this study was to assess the treatment response to conventional antiepileptic drugs and low-dose adrenocorticotropic hormone therapy for infantile spasms in children with Down syndrome. We retrospectively investigated the response and relapse rates, electroencephalography findings, patient characteristics during drug withdrawal, and developmental outcome in 10 children with Down syndrome treated for infantile spasms in our hospital. All patients showed cessation of infantile spasms and achieved electroencephalographic normalization. Spasm relapse occurred in one of 10 patients (10%). Antiepileptic drugs have been withdrawn for seven of 10 patients (70%), none of whom have experienced seizure relapse since drug withdrawal. The median developmental quotient (n = 8) was 20.5, which shows that the developmental outcome was unfavorable. Low-dose adrenocorticotropic hormone therapy achieved a low seizure remission rate of 28.6%. Elucidation of the optimal treatment for infantile spasms in children with Down syndrome is needed to reduce the duration of infantile spasms and improve the developmental outcome.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to assess the treatment response to conventional antiepileptic drugs and low-dose adrenocorticotropic hormone therapy for infantile spasms in children with Down syndrome.
METHODS METHODS
We retrospectively investigated the response and relapse rates, electroencephalography findings, patient characteristics during drug withdrawal, and developmental outcome in 10 children with Down syndrome treated for infantile spasms in our hospital.
RESULTS RESULTS
All patients showed cessation of infantile spasms and achieved electroencephalographic normalization. Spasm relapse occurred in one of 10 patients (10%). Antiepileptic drugs have been withdrawn for seven of 10 patients (70%), none of whom have experienced seizure relapse since drug withdrawal. The median developmental quotient (n = 8) was 20.5, which shows that the developmental outcome was unfavorable. Low-dose adrenocorticotropic hormone therapy achieved a low seizure remission rate of 28.6%.
CONCLUSIONS CONCLUSIONS
Elucidation of the optimal treatment for infantile spasms in children with Down syndrome is needed to reduce the duration of infantile spasms and improve the developmental outcome.

Identifiants

pubmed: 33638247
doi: 10.1111/ped.14668
doi:

Substances chimiques

Anticonvulsants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1495-1503

Informations de copyright

© 2021 Japan Pediatric Society.

Références

Daniels D, Knupp K, Benke T, Wolter-Warmerdam K, Moran M, Hickey F. Infantile spasms in children with Down syndrome: Identification and treatment response. Glob. Pediatr. Health 2019; 6: 2333794X1882193. https://doi.org/10.1177/2333794X18821939.
Tapp S, Anderson T, Visootsak J. Neurodevelopmental outcomes in children with Down syndrome and infantile spasms. J. Pediatr. Neurol. 2015; 13: 74-7.
Sanmaneechai O, Sogawa Y, Silver W, Ballaban-Gil K, Moshé SL, Shinnar S. Treatment outcomes of West syndrome in infants with Down syndrome. Pediatr. Neurol. 2013; 48: 42-7.
Eisermann MM, DeLaRaillère A, Dellatolas G et al. Infantile spasms in Down syndrome-effects of delayed anticonvulsive treatment. Epilepsy Res. 2003; 55: 21-7.
Arya R, Kabra M, Gulati S. Epilepsy in children with Down syndrome. Epileptic Disord. 2011; 13: 1-7.
Tatsuno M, Hayashi M, Iwamoto H, Suzuki Y, Kuroki Y. Epilepsy in childhood Down syndrome. Brain Dev. 1984; 6: 37-44.
Hamano SI, Nagai T, Matsuura R et al. Treatment of infantile spasms by pediatric neurologists in Japan. Brain Dev. 2018; 40: 685-92.
Silva ML, Cieuta C, Guerrini R, Plouin P, Livet MO, Dulac O. Early clinical and EEG features of infantile spasms in Down syndrome. Epilepsia 1996; 37: 977-82.
Verrotti A, Cusmai R, Nicita F et al. Electroclinical features and long-term outcome of cryptogenic epilepsy in children with Down syndrome. J. Pediatr. 2013; 163: 1754-8.
Yamada K, Toribe Y, Kimizu T et al. Predictive value of EEG findings at control of epileptic spasms for seizure relapse in patients with West syndrome. Seizure. 2014; 23: 703-7.
Camfield P, Camfield C, Lortie A, Darwish H. Infantile spasms in remission may reemerge as intractable epileptic spasms. Epilepsia 2003; 44: 1592-5.
Nabbout R, Melki I, Gerbaka B, Dulac O, Akatcherian C. Infantile spasms in Down syndrome: Good response to a short course of vigabatrin. Epilepsia 2001; 42: 1580-3.
Verrotti A, D'Egidio C, Agostinelli S et al. Antiepileptic drug withdrawal in childhood epilepsy: what are the risk factors associated with seizure relapse? Eur. J. Paediatr. Neurol. 2012; 16: 599-604.
Goldberg-Stern H, Strawsburg RH, Patterson B et al. Seizure frequency and characteristics in children with Down syndrome. Brain Dev. 2001; 23: 375-8.
Stafstrom CE, Konkol RJ. Infantile spasms in children with Down syndrome. Dev. Med. Child. Neurol. 1994; 36: 576-85.
Riikonen R. Infantile spasms: outcome in clinical studies. Pediatr. Neurol. 2020; 108: 54-64.
Kanai Y, Mutsuzaki H, Nakayama T, Yozu A, Iwasaki N. Relationship between the use of lower extremity orthoses and the developmental quotient of the Kyoto Scale of Psychological Development in children with Down syndrome. J. Phys. Ther. Sci. 2018; 30: 1019-23.
O'Callaghan FJ, Lux AL, Darke K et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011; 52: 1359-64.

Auteurs

Satomi Nishimoto (S)

Department of Pediatrics, Osaka Medical College Hospital, Takatsuki-City, Osaka, Japan.

Shuichi Shimakawa (S)

Department of Pediatrics, Osaka Medical College Hospital, Takatsuki-City, Osaka, Japan.

Miho Fukui (M)

Department of Pediatrics, Osaka Medical College Hospital, Takatsuki-City, Osaka, Japan.

Motoko Ogino (M)

Department of Pediatrics, Osaka Saiseikai Suita Hospital, Suita, Osaka, Japan.

Hikaru Tsuda-Kitahara (H)

Department of Pediatrics, Osaka Medical College Hospital, Takatsuki-City, Osaka, Japan.

Hiromitsu Toshikawa (H)

Department of Pediatrics, Osaka Saiseikai Suita Hospital, Suita, Osaka, Japan.

Shohei Nomura (S)

Department of Pediatrics, Hirakata City Hospital, Hirakata, Osaka, Japan.

Kayo Kunisada (K)

Department of Pediatrics, Seikeikai Hospital, Sakai, Osaka, Japan.

Mitsuru Kashiwagi (M)

Department of Pediatrics, Hirakata City Hospital, Hirakata, Osaka, Japan.

Ryohei Miyamoto (R)

Department of Pediatrics, Miyamoto Children's Clinic, Fushimi, Kyoto, Japan.

Hiroshi Tamai (H)

Department of Pediatrics, Osaka Medical College Hospital, Takatsuki-City, Osaka, Japan.

Akira Ashida (A)

Department of Pediatrics, Osaka Medical College Hospital, Takatsuki-City, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH